CureMatch
×
  • Physicians
  • Patients
  • Employers
  • About Us
  • News
    • CureMatch News
    • Validation and Research
    • Events & Conferences
  • Contact
  • Login
Jean-Pierre (JP) Millon

Jean-Pierre (JP) Millon

DIRECTOR, CVS HEALTH INVESTORS

Mr. Jean-Pierre Millon, also known as JP, was a Special Limited Partner of Care Capital, LLC and a Co-founder of BLS LLC. Mr. Millon joined PCS Health Systems, Inc. in 1995, where he served as its President and Chief Executive Officer from June 1996 to September 2000. He served as an Executive and held several leadership positions with Eli Lilly and Company including the position of Chief Executive Officer. He was named to that post in June 1996 following a year as Chief Operating Officer of PCS. Mr. Millon’s career with Lilly and its subsidiaries spanned two decades and was highlighted by leadership positions in the United States and executive posts in the Orient, Europe and the Caribbean Basin. Most recently, he served as President and General Manager of Lilly Japan, K.K. and Vice President of the Lilly pharmaceutical division in Kobe, Japan. He directed strategic planning, personnel, Japan business planning and marketing research efforts at Lilly headquarters in Indianapolis. Prior to those corporate directorships, he served as General Manager of the Caribbean Basin in Puerto Rico. He served in financial leadership roles in West Germany, Belgium and France. He has been Chairman of Business Advisory Board at Regen BioPharma, Inc. since October 16, 2017. Mr. Millon serves as the Chairman of the Board of Medical Present Value, Inc. He serves as a Director of Triple Aim Ventures, LLC/TAV Health. He served as the Chairman of Prometheus Laboratories Inc. Mr. Millon served as the Chairman of Protemix Corporation Limited since January 31, 2006. He serves as a Proove Biosciences, Inc., Director of M.P. Video Inc, iPhysicianNet Inc., a Scottsdale, Aeneas Buyer Corp. (also known as Health Systems International, LLC) and CVS Caremark, Inc. He has been a Director of Caremark Rx, L.L.C. since March 2004. CaremarkPCS, LLC since March 2004, InfuSystem, Inc. since September 2005, CVS Health Corporation since March 2007 and Prometheus Laboratories Inc. since March 2003. He serves as a Director of Caremark Rx, Inc. and Portable Genomics Inc. He was Member of Chief Executive Officer Advisory Board at Great Point Partners, LLC since 2006. He has served on a number of public companies’ (INFU, CYPB).He was a Director of Equian, LLC. Mr. Millon served as Lead Director of Cypress Bioscience, Inc., from April 2005 to August 18, 2010 and its Director from March 2004 to August 18, 2010. He is also involved with several not-for-profit organizations, covering health care, higher education and international affairs. He served as a Director of InfuSystem Holdings, Inc. from September 2005 to April 24, 2012. He served on the board of AdvancePCS for three years beginning in October 2000 and was an Advisor and Board Member of AdvancePCS. He is a Member of Northwestern’s J.L. Kellogg Graduate School of Management Alumni Advisory Board, Dean’s Council of 100 of the College of Business at Arizona State University, the Phoenix Symphony Board, the Barrow Neurological Foundation Board of Trustees and the International Advisory Council for the Barrow Neurological Institute. Mr. Millon earned an M.B.A in finance from the Kellogg School of Management at Northwestern University, a degree in Mechanical Engineering from Ecole Centrale de Lyon, France and a degree in Economics from the University of Lyon, France.

logo

+1 (858) 284-0488

FAX: +1 (858) 430-5813

Quick Links

  • Physicians
  • About CureMatch
  • News and Latest Posts
    • CureMatch News
    • Validation and Case Studies
    • Events and Conferences
  • Contact Us
  • FAQ

Latest News and Results

  • CureMatch Granted CPT® Code by American Medical Association for its Algorithmic Cancer Therapy Ranking Service Jan 4

    Oncologists will be able to submit claims to payers using a Category III CPT code,...

  • CureMatch CEO Navid Alipour named a Top 50 Honoree Leader of Influence in Life Science by San Diego Business Journal Jul 26

    Congratulations to CureMatch CEO Navid Alipour for being named a Top Leader of Influence in...

  • CureMatch Announces the Addition of John S. Link, Jordan Shlain and Greg Simon to Advisory Board Jul 21

    Dr. Link, Dr. Shlain and Mr. Simon all bring deep entrepreneurial experience in the medical...

© 2021 CureMatch, Inc. CureMatch is a registered trademark.
Terms of Use | Privacy Policy | HIPAA Notice

We’d like to send you a CureMatch Sample Analysis

 

Sample Analysis Download Form

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data